Current Lipid Management Guidelines in Atherosclerotic Cardiovascular Disease
Asian Journal of Cardiology Research,
The use of coronary artery calcium (CAC) score to reclassify risk individuals at either borderline or intermediate risk, for whom the danger of statin therapy is unknown, is another significant addition to the 2018 recommendations. Increased risk of recurrent cardiovascular (CV) events is linked to having established atherosclerotic cardiovascular disease (ASCVD). Many modifiable risk factors for cardiovascular disease have been connected in the literature, including blood pressure, low-density lipoprotein (LDL), high-density lipoprotein (HDL), glucose intolerance, and smoking. High dose statins and strict adherence to dietary and lifestyle changes have been shown to reduce the risk of coronary events, with the advent of newer lipid-lowering medications, statins may one day become obsolete.
- High-density lipoprotein
- cardiovascular disease
- coronary artery calcium
How to Cite
Murphy SL, Xu J, Kochanek KD, Arias E, Tejada-Vera B. Deaths: Final data for 2018. National Vital Statistics Reports. Available:https://www.cdc.gov/nchs/data/
WHO world health organization non-communicable diseases (NCD), country profile; 2015.
Pepine CJ. The effects of angiotensin-converting enzyme inhibition on endothelial dysfunction: potential role in myocardial ischemia. Am J Cardiol. 1998;82(10A): 23S-27S.
Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med. 1999;340(2):115-126. DOI:101056/NEJM199901143400207
Stary HC, Chandler AB, Dinsmore RE, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1995;92(5):1355-1374. DOI:101161/01.cir.92.5.1355
Okazaki S, Yokoyama T, Miyauchi K, et al. Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: The ESTABLISH Study. Circulation. 2004;110(9):1061-1068.
Vasan RS, Sullivan LM, Wilson PW, et al. Relative importance of borderline and elevated levels of coronary heart disease risk factors, Annals of Internal Medicine. 2005;142(6):393–402.
Carroll MD, Fryar CD, Nguyen DT, National Center for Health Statistics (U.S.), "Total and high-density lipoprotein cholesterol in adults: the United States, 2015-2016," in U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics; 2017.
Centers for Disease Control and Prevention (CDC. (2011), "Disparities in diagnoses of HIV infection between blacks/A- African Americans and other racial/ethnic populations–37 states, 2005-2008," MMWR. Morbidity and mortality weekly report. 2011;60(4):93–98.
Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459-2472.
Grundy SM, Stone NJ, Bailey AL, et al; 2018AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1082-e1143. Erratum in: Circulation. 2019;139:e1182-e1186.
Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for managing dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020:41:111-188. Erratum in: Eur Heart J. 2020:41:4255.
Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937-952.
Kolodgie FD, Virmani R, Burke AP, et al. Pathologic assessment of the vulnerable human coronary plaque. Heart. 2004;90 (12):1385-1391. DOI:10.1136/hrt.2004.041798
Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines [published correction appears in Circulation. 2004;110(6):763]. Circulation. 2004;110(2):227-239. doi:10.1161/01.CIR.0000133317.49796.0E
Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006;48(3):438-445. DOI:101016/j.jacc.2006.04.070
European Society of Cardiology/ European Atherosclerosis Society (ESC/EAS) Guidelines; 2019.
Muneera Al Taweel, Sarah AlMukhaylid, Nada Alsultan. Latest in High-Risk Atherosclerotic Cardiovascular Disease Lipid GuidelinesMini Review. Open J Cardiol Heart Dis. 2022;3(5). JCHD.000572.
American Heart Association/ American College of Cardiology (AHA/ACC) Guidelines; 2018.
Raviglione MC, O'Brien RJ, Longo D, Fauci A, Kasper D, Hauser S. Harrison's principles of internal medicine, McGraw-Hill Education. 2012;1:2888–2892.
Ference BA,. Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel, European Heart Journal. 2017;38(32):2459–2472.
Libby P, Buring JE, Badimon L, et al. "Atherosclerosis," Nature Reviews Disease Primers. 2019;5:1.
Karr S. Epidemiology and management of hyperlipidemia. The American Journal of Managed Care. 2017;23;9 Supplement: S139–S148, 2017.
Hill MF, Bordoni B. Hyperlipidemia, StatPearls Publishing; 2020.
Halcox JP, Banegas JR, Roy C, et al. Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EUREKA, a cross-sectional observational study, BMC Cardiovascular Disorders. 2017;17:1.
Grundy SM, Stone NJ, Bailey AL, et al. Guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines, Journal of the American College of Cardiology. 2019;73(24):e285–e350.
Rosenson RS, Hegele RA, Fazio S, Cannon CP. The Evolving Future of PCSK9 Inhibitors. J Am Coll Cardiol. 2018;72:314-329.
Robinson JG, et al. JAMA. 2014;311:1870-1882. Raal FJ, et al. Lancet. 2015;385:331-34
Shreya D, Zamora DI, Patel GS, et al. Coronary Artery Calcium Score - A Reliable Indicator of Coronary Artery Disease?; 2021.
Nissen SE et al. Presented at American Heart Association Annual Scientific Sessions; 2016, New Orleans, LA.
Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713-1722.
Puri R, Nissen SE, Ballantyne CM, et al. Factors underlying regression of coronary atheroma with potent statin therapy. Eur Heart J. 2013;34(24):1818-1825.
Gencer B, et al. Poster presented at American Heart Association Scientific Sessions; 2019. Philadelphia, PA
Ray KK, Wright RS, Kallend D, et al. Two phases 3 trials of inclisiran in patients with elevated LDL cholesterol, New England Journal of Medicine. 2020;382(16):1507–1519.
Lamb YN. Inclisiran: First Approval [published correction appears in Drugs. 2021;81(9):1129]. Drugs. 2021;81(3):389-395.
FDA,US food and drug administration; 2022.
Real FJ, Rosenson RS, Reeskamp LF, et al. Evinacumab for homozygous familial hypercholesterolemia, New England Journal of Medicine. 2020;383(8):711–720.
Jia X, AlRifai M, Hussain A, Martin S, Agarwala A, Virani SS. Highlights from studies in cardiovascular disease pre- vention presented at the Digital 2020 European Society of Car- diology Congress: prevention is alive and well, Current Atherosclerosis Reports. 2020;22:12.
Stein E, Bays H, Koren M, Bakker-Arkema R, Bisgaier C. Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients. Journal of Clinical Lipidology. 2016;10(5):1212–1222.
Laufs U, Banach M, Mancinietal GJ. "Efficacyandsafety of bempedoic acid in patients with hypercholesterolemia and statin intolerance," Journal of the American Heart Association. 2019;8:7, article e011662.
NEXLETOL (bempedoic acid) [Prescribing Information]. Ann Arbor, MI: Esperion Therapeutics
VASCEPA (icosapent ethyl) [Prescribing Information]. Bridgewater, NJ: Amarin Pharma, Inc; 2019.
Rubins H, Robins S, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low high-density lipoprotein cholesterol levels. Veterans Affairs High-density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341:410-418.
Robinson J. Management of complex lipid abnormalities with a fixed-dose combination of simvastatin and extended-release niacin. Vasc Health Risk Man. 2009;5:31-43.
Abstract View: 32 times
PDF Download: 7 times